Ziftomenib + Mezigdomide for Acute Myeloid Leukemia

This trial explores the safety and tolerability of a new treatment that combines ziftomenib and mezigdomide for people with certain types of acute myeloid leukemia (AML). The focus is on participants whose AML has specific genetic changes, such as KMT2A-rearrangements or NPM1 mutations, and who have not responded to previous treatments. Those with AML that persists or recurs despite other therapies might be suitable candidates. Participants will take both medications orally, with the schedule confirmed by the study doctor. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial protocol does not specify if you need to stop taking your current medications, but it does mention a 7-day period without proton pump inhibitors and potassium-competitive acid blockers before starting the study treatment.

Research shows that ziftomenib, when used alone, is generally well tolerated. Previous studies found that it doesn't cause serious heart rhythm problems or other major side effects. Some patients experienced differentiation syndrome during treatment, but it was manageable and not severe.

For mezigdomide, less safety information is available. Since this trial is in the early stages (Phase 1), the main goal is to ensure the combination is safe for humans. Early-stage trials usually involve close monitoring to catch any potential side effects.

Researchers are excited about Ziftomenib and Mezigdomide for treating Acute Myeloid Leukemia (AML) because they offer a fresh approach compared to current treatments like chemotherapy and targeted therapies. Ziftomenib works by targeting a specific protein called menin, which plays a role in the growth of AML cells, potentially halting their progression. Mezigdomide is designed to modulate the immune system, enhancing its ability to fight cancer cells. This combination of targeting cancer growth and boosting immune response is what sets these treatments apart, offering hope for more effective and potentially faster-acting options for AML patients.

Research has shown that the drug ziftomenib effectively treats NPM1-mutant acute myeloid leukemia (AML). In one study, 63% of patients responded well, and 23% went into complete remission, meaning their cancer was no longer detectable. Another drug, mezigdomide, has also shown promise, particularly in certain lab studies involving specific AML cell types. In this trial, participants will receive a combination of ziftomenib and mezigdomide, which might be a strong option for fighting these specific types of AML. Early research suggests that this combination could effectively manage AML that has returned or is not responding to other treatments.¹³⁶⁷⁸